Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
02 févr. 2024 16h15 HE
|
Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...
Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap
18 janv. 2024 17h00 HE
|
Axogen, Inc.
REPOSE® met its primary endpoint of non-inferiority between the pain visual analog scale outcomes for neurectomy with Axoguard Nerve Cap® vs. standard-of-care neurectomy at Month 12. Axoguard Nerve...
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023
04 janv. 2024 16h45 HE
|
Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...
Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025
04 janv. 2024 16h40 HE
|
Axogen, Inc.
ALACHUA and TAMPA, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today...
Axogen Announces Promotions on Research and Development Team
04 janv. 2024 16h35 HE
|
Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve...
Axogen, Inc. Appoints Kathy Weiler to its Board of Directors
26 déc. 2023 16h15 HE
|
Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...
Axogen Announces Transition of Finance Team Leadership
06 déc. 2023 07h00 HE
|
Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...
Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 déc. 2023 17h00 HE
|
Axogen, Inc.
ALACHUA and TAMPA, Fla., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today...
Axogen, Inc. to Participate at the Piper Sandler 35th Annual Healthcare Conference
20 nov. 2023 07h00 HE
|
Axogen, Inc.
ALACHUA and TAMPA, Fla., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today...
Axogen, Inc. Reports 2023 Third Quarter Financial Results
07 nov. 2023 07h00 HE
|
Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...